Bazedoxifene as a Concomitant Treatment of Patients With Metastatic Pancreatic Adenocarcinoma
Status:
Not yet recruiting
Trial end date:
2024-05-31
Target enrollment:
Participant gender:
Summary
Bazedoxifene, a selective estrogen receptor modulator is thought to have effective
anti-tumoral properties for pancreatic cancer via IL-6 pathway (GP130/STAT3) inhibition.
The objective is to measure IL-6 (GP130/STAT3)-pathway modification on metastasis biopsy of
patients with metastatic pancreatic adenocarcinoma before and after treatment with
bazedoxifene in addition to chemotherapy.
This study is a single-center, prospective, nonrandomized trial.